ArticleBMC infectious diseases2025
The treatment success rate and associated factors among pulmonary bacteriologically confirmed and pulmonary clinically diagnosed drug susceptible TB coinfected with HIV in Teso Sub-Region, North-Eastern Uganda 2020-2021. a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of prior TB preventive therapy on all-cause mortality during TB treatment among people with HIV/TB in rural eastern Uganda: an observational causal analysis.BMC infectious diseases · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a global public health burden, with 500,000 people dying of Tb in 2021. People living with HIV have an 18 times higher risk of having TB, which is associated with poor treatment outcomes. This study aimed to determine the treatment success rate and associated factors among Pulmonary Clinically Diagnosed and Bacteriologically Confirmed TB individuals coinfected with HIV in the Teso region, Northeastern Uganda.
methodsWe conducted a retrospective study in Twenty-two (22) accredited diagnostic and Tuberculosis Unit health facilities located in 11 districts of the Teso region, Northeastern. Data was collected from the health facility's Tb treatment register using a data abstraction tool in February 2024 for individuals with drug-susceptible tuberculosis who started Tb treatment from January 2020 to December 2021. Additional information relating to the patients was collected from the Client Care Cards. The primary outcome was treatment success (Yes and No). Continuous Data was summarized into mean and standard deviation and categorical variables into proportions and frequencies. Binary logistic regression analysis was conducted to determine factors associated with TSR and reported as adjusted odds ratios (aOR). A p < 0.05 was considered statistically significant.
resultsA total of 801 individuals were included in the analysis, with a median age of 42 years (interquartile range 33-52). Among these, 61.67% (n = 494) were aged 15-49. The majority of individuals, 53.43% (n = 428), were males, with 67.92% (n = 544) having PBC. Among all participants, 40.5% (n = 325) had been on treatment for more than 5 years. The Overall treatment success rate was 84.39%. Factors that were associated with successful TSR were receiving services at a specialized clinic (adjusted Odds Ratio (aOR) : 2.10, 95%CI; 1.03-4.23, P = 0.041), having New TB (aOR: 3.30, 95%CI; 1.17-9.39, P = 0.025) and relapsed TB (aOR: 9.71, 95%CI; 2.03-46.24, P = 0.004) and having viral load suppression (aOR :2.85, 95%CI; 1.64-4.97, P = 0.001).
conclusionReceiving treatment in a specialized HIV clinic, having New and relapsed TB, and having a suppressed viral load were associated with a successful treatment rate. There is a need to scale up integrated TB/HIV differentiated services, ensure Viral load suppression through adherence support for the TB/HIV coinfected clients, and increase Tb awareness to achieve the end TB Strategy by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.